The blood group typing market is becoming increasingly important as healthcare systems manage growing transfusion requirements associated with chronic diseases, surgery, trauma, pregnancy-related complications, and organ transplantation. Blood Group Typing Market provides the foundation for identifying donor and recipient compatibility and plays an essential role in transfusion safety. The global market was valued at USD 2.3 billion in 2025 and is projected to reach USD 5.6 billion by 2033, growing at a 12.0% CAGR from 2026 to 2033. North America dominated the market with a 44.2% revenue share in 2025, while Asia Pacific is projected to experience the fastest growth.
Key Highlights
USD 2.3 billion in 2025 → USD 2.5 billion in 2026 → USD 5.6 billion by 2033, reflecting a 12.0% CAGR. Reagents & consumables represented 72.2% of product revenue in 2025, antibody screening accounted for 38.9% of test-type revenue, and North America represented 44.2% of the global market. Asia Pacific is emerging as the fastest-growing regional opportunity, with the region projected to reach nearly USD 1.3 billion by 2033 at a 13.4% CAGR.
One Blood Unit Creates a Chain of Testing
Blood donation → blood collection → ABO/Rh typing → antibody screening → compatibility testing → blood storage → transfusion
Every stage depends on accurate identification.
Before donated blood reaches a patient, laboratories need to establish blood-group characteristics and assess compatibility. This makes blood group typing a recurring requirement across blood banks, hospitals, diagnostic laboratories, and transfusion centers rather than a one-time diagnostic activity.
The growing volume of blood donations and transfusions is therefore creating a dependable base for market demand. Grand View Research notes that more than 118.5 million blood donations are collected globally each year, reinforcing the enormous scale of blood-group testing requirements.
Download a free sample report or claim your copy of this full market intelligence report
Chronic Disease Is Expanding the Need for Repeat Testing
The demand story begins with patients who require blood repeatedly.
Anemia, cancer, thalassemia, sickle cell disease, and other hematological conditions can increase dependence on transfusion support. Repeated transfusions may also increase the importance of more detailed compatibility assessment because patients can develop antibodies against blood-group antigens over time.
This creates a progression:
Chronic disease burden rises → transfusion requirements increase → compatibility testing increases → blood typing utilization expands
The same relationship applies to major surgery, trauma care, and transplantation.
Surgery and Trauma Add an Emergency Dimension
Blood group typing is not limited to planned healthcare.
Emergency departments may need compatible blood quickly after severe trauma. Surgical procedures may also require blood availability in advance. Organ transplantation introduces another layer of compatibility considerations.
According to the source data, 173,727 solid organ transplants were performed globally in 2024, highlighting the scale of procedures that require sophisticated compatibility workflows.
As healthcare systems increase surgical capacity and emergency-response capabilities, the demand for accurate and rapid blood typing follows the same direction.
Reagents and Consumables Keep the Market Recurring
The reagents & consumables segment held 72.2% of market revenue in 2025.
Its dominance is linked to repeated use across routine blood-grouping workflows. Reagent red blood cells, antisera, controls, gel cards, cartridges, and other consumables are required continuously for testing.
This gives the segment a strong recurring revenue structure.
The market therefore does not depend entirely on instrument purchases. A growing installed base of analyzers and expanding transfusion activity can continue generating demand for consumable products.
Automation Is Changing the Laboratory Workflow
The traditional model of manual interpretation is gradually giving way to automated systems.
Manual testing → automated sample handling → automated reaction analysis → software-assisted interpretation → higher-throughput workflow
Automation can reduce repetitive manual work and support more standardized testing.
The opportunity is particularly strong in busy blood banks and diagnostic laboratories where high testing volumes make turnaround time and consistency important.
Molecular Typing Opens Another Market Layer
Serological testing remains central, but molecular approaches are expanding the boundaries of blood group typing.
PCR, microarray, and next-generation sequencing technologies can help identify genetic variants and rare blood-group characteristics that may be difficult to resolve through conventional methods.
This is particularly valuable for patients who require repeated transfusions or those with uncommon antigen profiles.
The opportunity can be expressed as:
Routine serology → complex cases → molecular confirmation → rare antigen identification → precision-matched transfusion
That progression is increasing the strategic value of genotyping technologies.
Antibody Screening Holds a Critical Position
The antibody screening segment accounted for 38.9% of revenue in 2025.
The importance of antibody screening lies in its ability to identify unexpected antibodies that could create transfusion complications.
It is used before transfusion and in other clinical situations where compatibility matters.
As blood transfusion safety standards become more sophisticated, antibody identification and extended antigen characterization are becoming increasingly important components of laboratory workflows.
Regional Market Direction
North America: North America remains the dominant regional market with a 44.2% share in 2025. Strong healthcare infrastructure, established blood-bank networks, high transfusion activity, and adoption of automated and molecular diagnostics support the region's leadership.
Asia Pacific: Asia Pacific is projected to be the fastest-growing region. Grand View Research estimates that the regional market will reach USD 1,298.9 million by 2033, expanding at a 13.4% CAGR from 2026 to 2033. Rising healthcare expenditure, improving diagnostic infrastructure, and expanding blood-transfusion services are supporting this growth.
Europe: Mature blood services, stringent transfusion-safety standards, and adoption of automated laboratory systems continue to support demand.
Latin America: Improving blood-bank infrastructure and expanding access to diagnostic services are creating gradual opportunities.
Middle East & Africa: Healthcare investment and modernization of transfusion services are widening access to advanced blood typing solutions.
The Cost of Advanced Testing Remains a Barrier
Molecular and high-throughput typing technologies can require specialized instruments, trained laboratory staff, software, and supporting infrastructure. These costs can limit penetration in smaller laboratories and resource-constrained healthcare systems.
This creates a market divide:
Basic routine testing → broad accessibility
Advanced molecular testing → higher precision but greater investment
Manufacturers that can lower the cost and complexity of advanced testing may unlock significant adoption opportunities.
The Market's Next Step
The blood group typing market is gradually moving from basic blood-group identification toward increasingly detailed compatibility profiling.
More transfusions → more testing → greater need for automation → greater need for molecular characterization → more precise transfusion support
The long-term opportunity lies in technologies that can make this chain faster, more accurate, and easier to scale.
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.